Rival sources tangle over claim that Celgene is mulling ‘horrid’ HGS bid

Human Genome Sciences ($HGSI) has been hunting a white knight for weeks now. Faced with what it sees as a low-ball, $2.6 billion bid from GlaxoSmithKline ($GSK), which the pharma giant stubbornly refu…
Read the full story: News